BAMB-4
产品说明书
 |
同义名 : | ITPKA-IN-C14 |
| CAS号 : | 891025-25-5 | |
| 货号 : | A667119 | |
| 分子式 : | C15H12N2O2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 252.27 | |
| MDL号 : | MFCD08362411 | |
| 存储条件： |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | BAMB-4 is a new membrane-permeable inhibitor against inositol-1,4,5-trisphosphate-3-kinase A((ITPKA) with IC50 of 37 μM in ADP-Glo Assay. Only BAMB-4 was nearly completely taken up by H1299 cells and remained stable after cellular uptake, thus exhibiting a robust stability and a high membrane permeability. Determination of the inhibitor type revealed that BAMB-4 belongs to the group of mixed type inhibitors. BAMB-4 is also a membrane-permeable InsP3Kinase inhibitor with IC50-value of 20 μM[2]. ITPKA inhibitor BAMB-4 exhibit the lowest inhibition frequency among the InsP3- Kinase inhibitors. Only in one from 42 targets tested, BAMB-4 showed an inhibitory effect. Noteworthy, in kinase screens no targets of BAMB-4 were detected, indicating that the compound does not belong to the typical kinase inhibitors. Thus, the relative high specificity and the high cellular uptake of BAMB-4 now for the test provide the possibility to effectively inhibit InsP3kinase in vivo. The InsP3Kinase activity is essentially involved in ITPKA promoted metastasis of lung cancer cells, BAMB-4 is a promising therapeutic approach in lung cancer therapy[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.96mL 0.79mL 0.40mL |
19.82mL 3.96mL 1.98mL |
39.64mL 7.93mL 3.96mL |
| 参考文献 |
|---|